T1	intervention 13 28	zoledronic acid
T2	eligibility 454 500	Patients with EBC and DTC-positive bone marrow
T3	No-of-participants 522 524	96
T4	control 582 613	adjuvant systemic therapy alone
T5	outcome-Measure 619 640	change in DTC numbers
T6	intervention-value 820 823	67%
T7	control-value 831 834	35%
T8	outcome 684 762	DTC-positive patients treated with ZOL were more likely to become DTC-negative
T9	outcome 862 872	DTC counts
T10	outcome 985 1017	ZOL was generally well tolerated
